Serplulimab plus Chemotherapy Improves OS and PFS in Elderly ES-SCLC
The biomarker NLR may not be suitable for prognosis prediction in elderly patients with small cell lung cancer, according to this real-world study.
Previous Post
Using Telemedicine to Keep Care Local
Next Post
Efficient Strategies to Reduce Wait Time Between Diagnosis of Hidradenitis Suppurativa and Treatment
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago